Drugging the cancer genome: Strategies to overcome or prevent tumour evolution and drug resistance

Paul Workman - ICR

June, 15 2015
DKFZ Main Auditorium
Host: A. Miller

Biosketch Paul Workman

Professor Paul Workman is Chief Executive and President of The Institute of Cancer Research, Head of its Division of Cancer Therapeutics, and Harrap Professor of Pharmacology and Therapeutics. At ICR he is also Director of the Cancer Research UK Cancer Therapeutics Unit – the largest non-profit cancer drug discovery group in the world. Workman has been responsible for more than 20 new molecularly targeted anticancer drugs entering clinical trial. He is especially renowned for his innovative personal research in the discovery, chemical biology and molecular pharmacology of leading drugs acting on the molecular chaperone HSP90 (eg AUY922 licensed to Novartis) and PI3 kinase (eg pictilisib, GDC-0941; licensed to Genentech) and as the originator of the widely used Pharmacologic Audit Trail for biomarker-led drug development. Workman has won numerous rewards and fellowships.

to top
powered by webEdition CMS